Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair ...

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has once again snubbed Translarna (ataluren), PTC Therapeutics’ treatment for the genetic disease Duchenne ...

Investors and big pharma companies are waking up to the potential of techbio companies after years of avoidance, say experts ...

The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.

As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug ...

From exploring the wonders of plants as a curious teen to leading global initiatives at SCIEX, Gitte Barknowitz has carved ...

Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization ...

The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.